Psychomotor stimulant. Inhibitor of dopamine and noradrenalin transporters that increases the extracellular concentration of dopamine and noradrenalin. Increases locomotor activity in vivo.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 269.77. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.71 mL||18.53 mL||37.07 mL|
|5 mM||0.74 mL||3.71 mL||7.41 mL|
|10 mM||0.37 mL||1.85 mL||3.71 mL|
|50 mM||0.07 mL||0.37 mL||0.74 mL|
References are publications that support the biological activity of the product.
Askenasy et al (2007) Methylphenidate (Ritalin): behavioral studies in the rat. Int.J.Neurosci. 117 757 PMID: 17454243
Leonard et al (2004) Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Human Psychopharm. 19 151
If you know of a relevant reference for Threo-methylphenidate hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Threo-methylphenidate hydrochloride, Threo-methylphenidate hydrochloride supplier, inhibitors, inhibits, dopamine, DAT, noradrenalin, noradrenaline, NET, adrenalin, transporters, Psychomotor, stimulants, neurotransmitter, Ritalin, Dopamine, Transporters, Adrenergic, 1812, Tocris Bioscience
3 Citations for Threo-methylphenidate hydrochloride
Citations are publications that use Tocris products. Selected citations for Threo-methylphenidate hydrochloride include:
Parker et al (2014) Atomoxetine reduces anticipatory responding in a 5-choice serial reaction time task for adult zebrafish. PLoS One 231 2671 PMID: 24481568
Poulin et al (2014) Fluoxetine blocks Nav1.5 channels via a mechanism similar to that of class 1 antiarrhythmics. Mol Pharmacol 86 378 PMID: 25028482
Beerepoot et al (2016) Pharmacological Chaperones of the Dopamine Transporter Rescue Dopamine Transporter Deficiency Syndrome Mutations in Heterologous Cells. J Biol Chem 291 22053 PMID: 27555326
Do you know of a great paper that uses Threo-methylphenidate hydrochloride from Tocris? Please let us know.
Reviews for Threo-methylphenidate hydrochloride
There are currently no reviews for this product. Be the first to review Threo-methylphenidate hydrochloride and earn rewards!
Have you used Threo-methylphenidate hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.